Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. This activity is supported by independent medical ...